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Background. Parkinson’s disease is a neurodegenerative condition with both physical and mental consequences that affect many
aspects of everyday life. Persons with Parkinson’s disease and their care partners want guidance from healthcare services in order
to develop skills to adjust to life with a long-term condition. (e Swedish National Parkinson School is a dyadic self-management
programme to support both persons with Parkinson’s disease and care partners. Objective. To assess the outcomes of the Swedish
National Parkinson School as reported by participants.Design. A quasi-experimental case-control study in clinical care using self-
reported questionnaires. Participants. Swedish National Parkinson School was offered by health care professionals working in
clinical care. Participants in the programme were also asked to participate in the study. Amatched control group was recruited for
a comparison of findings. In total, 92 persons with Parkinson’s disease and 55 care partners were included. Settings. Five Swedish
geriatric and neurologic outpatient clinics. Method. Data were collected during 2015–2017, before and after participation in the
National Parkinson School or before and after seven weeks of standard care. Outcomes were assessed using generic and
Parkinson’s specific questionnaires. Descriptive statistics were used to describe baseline characteristics. Mann–Whitney U and
Chi2 tests were used to test for between-group differences and within-group differences were tested by theWilcoxon signed-ranks
test. Results. Improvements regarding health status, constructive attitudes and approaches, and skill and technique acquisition
were found after the intervention among persons with Parkinson’s disease. No changes were found among care partners.
Conclusion. (e findings indicate that the Swedish National Parkinson School may improve health status and self-management
among persons with Parkinson’s disease, but further studies are needed to better understand the effects of the programme.
1. Introduction
Parkinson’s disease (PD) is a long-term neurodegenerative
condition affecting about 1% of the population over 60 years
old. With a longer life expectancy in the general population,
the prevalence is expected to double over the coming de-
cades [1–3]. PD is associated with both physical and mental
consequences that affect many aspects of daily life [1, 4].
Motor symptoms (i.e., slowing of movements, rigidity,
resting tremor, balance, and gait problems) are mainly due
to the degeneration of dopaminergic neurons in the brain
[1]. However, nonmotor symptoms, such as fatigue, de-
pression, anxiety, cognitive impairment, pain, sleep dis-
turbances, and dysautonomia are also common and add
significantly to the burden of living with PD [4, 5].
Symptomatic medical therapy is initially successful but a
fluctuating drug response, dyskinesias, and other treatment
complications often develop over time [6]. (e occurrence
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and progression of both motor and nonmotor symptoms,
often in complex, unpredictable, and fluctuating patterns,
have significant consequences in daily life for persons with
PD (PwPD) as well as for their family members [7, 8].
Although PwPD need regular healthcare visits, including
evaluation of symptoms and adjustment of medical treat-
ment, day-to-day care and management is performed by the
persons themselves and their care partners [9, 10]. Ac-
cordingly, PwPD and their care partners need to develop
emotional, cognitive, and practical skills to adjust to living
with the disease. (e ability to handle everyday life and deal
with uncertainty of the future is vital in order to live well and
maintain life satisfaction despite PD [11–14].
Self-care is defined as “the practice of activities that
individuals initiate and perform on their own behalf in
maintaining life, health and well-being” [15]. For persons
affected by long-term conditions, self-care demands change
because of disease. (e ability to adjust and engage in self-
care activities is crucial. Self-care is a wide concept that
contains three key components: self-maintenance, self-
monitoring, and self-management. Self-maintenance in-
cludes activities concerning many aspects of life that a
person will have to perform in order to maintain health and
well-being [16]. Self-monitoring refers to cognitive processes
including observation and assessment of symptoms and
activities of daily living leading to self-awareness. Self-
management is defined as the ability of a person, in col-
laboration with family, society, and healthcare services, to
handle symptoms, treatments, lifestyle changes, psychoso-
cial strain, and other consequences of disease [17]. All three
components are frequently used in the literature concerning
people living with long-term disorders, and in nursing
practice [18, 19].
A central role of the nursing profession is to provide
assistance, support, and advice on health-related issues.
Changes in population demographics, with a growing
number of persons affected by long-term disorders as well as
limited resources and the changing organization of health
care have accentuated nurses’ need to facilitate and support
self-care in the outpatient care setting [20]. In supporting
persons with long-term conditions, nurses typically deal
with the impact of disease on everyday life as well as medical
aspects of the disease [21, 22]. Nurses are therefore con-
sidered suitable to guide patients and their families to ac-
tively engage in self-care [20, 23–25]. Patient education can
be a way to strengthen a person’s abilities and boost self-
efficacy in becoming actively involved in self-care [26].
Accordingly, nurses themselves acknowledge that their role
as an educator is a significant dimension of their profession
[24].
Self-management interventions are educational inter-
ventions designed to help persons with long-term disorders
to deal with the impact of disease in everyday life. To be
considered a self-management intervention the education
should target cognitive processes and inner motivation and
not just provide increased knowledge of the disease and
medication. Self-management interventions often include
techniques of goalsetting, self-monitoring, problem solving,
and action planning [27, 28].
In order to provide self-management education and
support to PwPD and their care partners, the European
EduPark consortium initiated the development of a
standardised educational programme in 2002. (is resulted
in the self-management programme “Patient Education for
Persons with PD and their carers” (PEPP) based on the
principles of cognitive behavioural therapy [29]. (e pur-
pose is to provide PwPD and their care partners with tools
and strategies to increase their ability to manage everyday
life with disease and to promote life satisfaction [30]. (e
programme was tested and evaluated in seven European
countries and was found feasible and suitable for most
PwPD and care partners [31, 32]. Studies have suggested that
PEPP can improve mood and reduce psychosocial strain
among both PwPD and care partners [33, 34] and improve
self-reported health status among PwPD [35]. (ese im-
provements were sustained for three months [36] but
returned to baseline after six months [35].
Inspired by PEPP and with self-monitoring as well as
self-management as central concepts, the Swedish National
Parkinson School (NPS) was developed in 2013 in collab-
oration between health care professionals, patient repre-
sentatives, and industry [37, 38] and has since then been
implemented in clinical practice across the country. A
previous study [39] has indicated that NPS participants
experience several benefits, including support from persons
in the same situation and improved social connections to
family, society, and health care services. Improved knowl-
edge of strategies and cognitive techniques to monitor
symptoms and change behaviours, which allowed them to
better understand and cope with PD, was also reported. It
also increased awareness of the need to adapt a positive
mindset and outlook on life and to prioritise activities that
promote feelings of well-being and satisfaction with life [39].
However, no formal quantitative outcome assessment of the
NPS similar to those of the PEPP has been conducted.
(e objective of this study was to assess outcomes of the
NPS from the perspective of the participants using self-
reported questionnaires regarding, for example, life satis-
faction, self-reported health status, emotional well-being,
health-directed behaviours, social integration, and support.
2. Materials and Methods
2.1. Design. (is study is a quasi-experimental case-control
study of outcomes of the NPS as offered in clinical practice to
PwPD and their care partners. In addition, data were also
collected from a matched control group.
2.2. Participants. All participants were invited to participate
in the NPS by health care professionals working at five
geriatric and neurologic outpatient clinics across Sweden.
(e NPS program was already an implemented intervention
in the clinical care and it was provided at the participating
clinics. (erefore, the researchers had no influence in the
invitations or the selection of participants since this was
made by the health care professionals. Similarly, the
reserachers were not involved in the delivery of the NPS
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program as it was provided at the participating clinics.(ose
who agreed to participate in NPS were also informed about
the study and contacted by the researchers. (e only in-
clusion criterion applied was a diagnosis of Parkinson’s
disease for the persons affected. (e only exclusion criterion
for both persons with Parkinson’s disease and care partners
was cognitive impairment affecting their ability to under-
stand and respond to the self-reported outcome instruments,
as assessed by the health care professionals at the clinic.
An age- and gender matched control group was
recruited using patient listings of PwPD cared for at a major
university hospital covering a large part of south eastern
Sweden according to the same inclusion and exclusion
criteria for the intervention group. See Figure 1 for the flow
of participants.
2.3. Data Collection. Data were collected during 2015–2017.
NPS participants were first contacted over telephone by the
first author one week before the start of the NPS with in-
formation about the study and its purpose. Written infor-
mation about the study and the questionnaires (see below)
were then mailed to the participants with instructions to
complete them and bring them to the first NPS session. (e
questionnaires were collected on-site by the first author
immediately before the first NPS session. At that time, the
stage of PD according to Hoehn and Yahr was also docu-
mented for PwPD [40]. Collecting the questionnaires in
person gave the participants an opportunity to ask further
questions about the study and clarify any uncertainties they
might have had about answering the questionnaires. After
the last session (seven weeks later), the same questionnaires
were mailed to the participants with instructions to complete
and return them within a week. All participants were asked
to fill in a short form if there had been any changes in their
medication or if there had been any outstanding events
making them feel unusually happy or sad recently. (e
intervention group included 59 PwPD and 35 care partners;
11 PwPD and five care partners dropped out of the NPS
before the end of the intervention or did not return follow-
up data.
(e control group did not participate in the NPS but
received standard care. (ey received written information
about the study and those who consented were asked to
complete questionnaires and return them by mail to the first
author within two weeks. Seven weeks later, they were
mailed the same questionnaires again and were asked to
complete and return them within two weeks. In total 48
PwPD and 29 care partners agreed to participate in the
control group; four in each group did not return follow-up
data and were excluded from the study.
Only participants with complete baseline and follow-up
assessments were included in the analysis; 48 PwPD and 30
care partners in the intervention group and 44 PwPD and 25
care partners in the control group. See Figure 1 for the flow
of participants.
2.4. Intervention. (e NPS is a self-management pro-
gramme for PwPD and their care partners that aims to
provide knowledge and tools to enhance their ability to live
and handle life with PD. (e programme builds on prin-
ciples of cognitive behavioural therapy and was developed
based on the PEPP [29, 37–39]. (e NPS promotes
awareness of thoughts, feelings, and actions in relation to the
impact of disease on daily life and introduces techniques of
self-monitoring in order to provide the knowledge and tools
needed to enhance the ability to live and handle life with the
disease. It does not primarily focus on the disease itself, but
on how to live a good life in the presence of disease. (e
programme is based on the idea that the participants need
both knowledge about the disease itself and an under-
standing of how it can affect their lives. Having a positive
mindset in life and engaging in meaningful and social ac-
tivities are promoted as ways to enhance satisfaction with
life. (e NPS consists of seven, two-hour sessions, where
PwPD and care partners gather in a small group with a
qualified instructor. (e instructor is a health care profes-
sional experienced with PD and trained to deliver the
programme. Each session focuses on a specific topic that is
first introduced by the instructor and then followed by group
discussions. Each session ends with a 15-minute relaxation
exercise. (e topic is then applied to the participants’ own
life situation through practical exercises and homework
assignments. (e seven themes of the NPS are presented in
Figure 2. For more information of the NPS programme, see
supporting information file (available here).
2.5. Assessments. Data were collected using seven generic
and PD specific questionnaires administered before and
after participation in the NPS (and at corresponding time
points for the control group). (e eight-item PD Ques-
tionnaire (PDQ-8) was only used by PwPD, and the Zarit
Burden Interview (ZBI) only by care partners. (e protocol
was partly inspired by previous studies investigating out-
comes of the PEPP [31, 33–35].
(e PDQ-8 is a specific questionnaire regarding per-
ceived PD related health status that was developed as a short
form of the PDQ-39 [41]. Each item has five response
categories (“never” through “always,” scored 0–4) that are
summed and transformed to a 0–100 range where higher
scores indicate worse health status.
(e EQ-5D is a five-item generic instrument for de-
scribing and valuing health states [42]. Each item has three
response categories that describe varying levels of problems
experienced for each item. It yields a utility value that
represents how each combination of responses has been
valued by representatives of the general population, from 1
(perfect health) to 0 (dead), as well as negative values
representing health states considered worse than death [43].
In this study, we used the experience-based scoring algo-
rithm proposed by Burstro¨m et al. [44].
(e ZBI is a generic questionnaire designed to evaluate
the burden that family caregivers may experience [45]. In
this study, we used the 12-item short form of the ZBI [46],
which has been found to exhibit psychometric properties
that are very similar to those of the original 22-item version
when used with care partners of PwPD [47]. Each item has
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five response categories (“never” through “nearly always,”
scored 0–4) that are summed into a total score that may
range between 0 and 48, where higher scores indicate higher
burden.
(e Health Education Impact Questionnaire (heiQ) is a
generic instrument designed to evaluate the efficacy of self-
management education for persons with long-term disor-
ders [48]. (e heiQ consists of 40 items representing eight
domains (Positive and active engagement in life, Health-
directed activities, skill and technique acquisition, Con-
structive attitudes and approaches, Self-monitoring and
insight, Health service navigation, Social integration and
support, emotional distress). Items are scored from 1
(“strongly disagree”) to 4 (“strongly agree”), and total scores
within each domain are also between 1 and 4. Higher scores
indicate greater self-management, except for the emotional
distress domain, where scoring is reversed. A Swedish
version of the heiQ has been evaluated among people with
various long-term disorders, including PwPD [49]. In ad-
dition, the heiQ-Programme evaluation questionnaire was
used at follow-up. (is questionnaire was designed to
evaluate the quality of programme delivery as perceived by
participants [48]. In this study, we extended the heiQ-
Programme with two questions specific to the NPS, asking
the participants whether their expectations of the program
had been met and whether it had improved their under-
standing of PD.
(e 11-item Life Satisfaction Checklist (LiSat-11) is a
generic questionnaire concerning the respondents’ satis-
faction with their current life situation as a whole as well as
within 10 specific areas [50]. Each area is scored from 1
(“very dissatisfied”) to 6 (“very satisfied”). (e questionnaire
has previously been used to assess satisfaction with life
among PwPD [51, 52].
Invited and willing to participate in
national parkinson school
Total 132 PwPD 75 care partners
asked to participate in study.
Intervention group
70 persons with PD
41 care partners
Control Group








Declined participation in study
14 PwPD 5 care partners
Declined participation in study
11 PwPD 6 care partners
7 weeks national parkinson school 7 weeks “standard care”
Post 7 weeks standard care
assessments returned
44 PwPD 25 care partners
Post NPS 7 weeks assessments
returned
48 PwPD 30 care partners
Total number of PwPD and care
partners included in study
Analyzed pre and posttest data in
total:
92 PwPD 55 care partners
Figure 1: Flow of participants.
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(e 16-item Parkinson Fatigue Scale (PFS-16) was de-
veloped to assess fatigue in PwPD but is also considered
useful for people who do not have PD [53–55]. Items were
scored from 0 (“strongly disagree”) to 4 (“strongly agree”),
yielding a possible total score between 0 and 64 (higher
scores�more fatigue).
In addition, participants completed a questionnaire on
demographic information (age, gender, education, living
conditions, etc.), comorbidities, and perceived general
health according to item 1 of the RAND-36 questionnaire
(“poor” through “excellent,” scored 0–4) [56, 57]. PwPD also
rated their difficulties in daily life using the PD Activities of
Daily Living Scale (PADLS; “no difficulties” through to
“extreme difficulties,” scored 1–5) [58, 59], perceived burden
due to PD (“none at all” through to “extreme,” scored 0–4),
frequency of memory problems according to item 32 of the
PDQ-39 (“never” through to “always,” scored 0–4) [60, 61],
and provided information on the presence or absence of
motor fluctuations and dyskinesias, time since diagnosis,
number of daily medication intakes, and current medical PD
therapy.
2.6. Sample Size. Sample size was estimated based on the
PDQ-8 using G∗Power version 3.1.9.4 [62]. Previous studies
have estimated the minimal important difference in PDQ-8
scores based on perceived improvement in health status and
disease severity to be about 7-8, corresponding to an effect
size of around 0.4 [63]. To detect such an effect at an alpha
level of 0.05 with 80% power requires a total sample size of at
least 35. To compensate for nonconsent, attrition, and un-
certainties in estimates we aimed at inviting twice that
number of PwPD to participate.
2.7. StatisticalAnalysis. Analyses were performed using IBM
SPSS version 23 (IBMCorp., Armonk, NY, USA). Due to the
ordinal nature of data and generally nonnormal distribu-
tional properties, nonparametric statistics were used.
Mann–Whitney U and Chi2 tests were used to test for be-
tween-group differences, while within-group differences
(pre-vs. postintervention) were tested by the Wilcoxon
signed-ranks test.
2.8. Ethical Considerations. (is study was approved by the
regional ethical review board and conducted in accordance
with the guidelines in the Declaration of Helsinki [64].
Participants received written and oral information about the
study and written consent were collected from all
participants.
3. Results
3.1. Attrition. In the intervention group, there was a total of
11 PwPD and five care partners without posttest data.
Reasons included nonreturn of follow-up questionnaires
(PwPD, n� 2; care partners, n� 1) and dropout from the
programme due to dissatisfaction with the programme’s
group format (PwPD, n� 1; care partners, n� 1), health
issues (PwPD, n� 3; care partners, n� 2), and unknown
reasons (PwPD, n� 5; care partners, n� 1). In the control
group, four PwPD and four care partners did not return their
follow-up questionnaires.
3.2. Background Characteristics. (e background charac-
teristics of all participants are reported in Table 1 and did not
differ between intervention and control groups except for a
larger proportion of male participants in the intervention
group. Age varied between 32 and 85 years in the whole
sample with a median age between 68 and 72 in the various
groups. PwPD reported between 1 and 11 daily medicine
intakes (median, four times/day) and having had their PD
diagnosis since 0–30 years with a median of five and seven
years in the intervention and control groups, respectively.
Hoehn and Yahr stages of PD varied between I and IV
(median, III) in the intervention group.
3.3. Outcomes among Persons with Parkinson’s Disease.
At baseline (Table 2), PwPD in the control group scored
higher on the LiSat-11 domain Life as a whole (P � 0.031)
and the heiQ domain skill and technique acquisition
(P � 0.002) than those in the intervention group. (ese
differences were no longer present at follow-up (Table 2).
Following participation in the NPS (Table 2), PwPD
reported improved health as indicated by both PDQ-8
(P � 0.028) and EQ5D (P � 0.023) scores. Additionally,
there were improvements in constructive attitudes and
approaches (P � 0.003) and skill and technique acquisition
(P< 0.001) of the heiQ. (e pattern of changes in other
outcomes also suggested improvements following partici-
pation in the NPS, but these failed to reach statistical sig-
nificance (Table 2).
In contrast, with the exception of emotional distress
(heiQ), outcomes in the control group exhibited a pattern of
deterioration over seven weeks of standard care (Table 2).











Figure 2: Overview of the themes and topics included in Swedish
National Parkinson School.
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leisure (P � 0.028), and contacts (P � 0.013) (LiSat-11)
reached significance.
3.4. Outcomes among Care Partners. (ere were no statis-
tically significant differences between the intervention and
control groups of care partners (Table 3). Scores in the care
partners intervention group tended to show slight im-
provements or remained stable following participation in the
NPS but did not reach levels of statistical significance. In the
control group, most scores stable or slightly worse following
seven weeks of standard care; of these, only satisfaction with
life as a whole (LiSat-11) was significantly lower (P � 0.035)
after seven weeks of standard care (Table 3).
3.5. Programme Evaluation. (e heiQ-Programme evalua-
tion questionnaire showed median values representing high
levels of satisfaction with the NPS among the PwPD as well
as care partners (Table 4). For example, both PwPD and care
partners agreed that participating in the NPS was worth-
while, that its content was relevant, and that their
Table 1: Background characteristicsa.









Age 71 (65–75) 68 (64–75) 0.506b 72 (68–77) 69 (67–74) 0.112b
Male gender, n (%) 24 (41) 32 (67) 0.007c 22 (63) 7 (24) 0.002c
Education, n (%)
Primary school (9 years) 15 (25) 8 (17) 0.540c 12 (34) 5 (17) 0.328c
High school (11–13 years) 19 (32) 18 (38) 8 (23) 7 (24)
University 25 (42) 22 (46) 15 (43) 16 (55)
Living with someone 52 (88) 41 (85) 0.678c 34 (97) 28 (97) 0.892c
Relation to person with PD, n
(%)
Spouse — — — 34 (97) 28 (97) 1.000c
Son/daughter — — 1 (3) 1 (3)
Housing, n (%)
Own house 33 (56) 32 (67) 0.162c — — —
Own apartment 15 (25) 13 (27) — —
Rental apartment 11 (19) 3 (6) — —
Comorbidity, n (%) 31 (53) 27 (60) 0.506c 19 (54) 17 (59) 0.728c
Perceived general healthd 1 (1–2) 2 (1–2) 0.242b 2 (2–3) 2 (2–3) 0.915b
PADLSe 2 (1–2) 2 (2–2) 0.918b — — —
Hoehn and Yahr stage of
PDf 3 (2–3) — — — — —
Time since diagnosis (years) 5 (2–7) 7 (3–8) 0.147b — — —
Perceived PD burdeng 2 (2–3) 2 (2–3) 0.829b — — —
Memory problems in last
30 daysh 2 (1–2) 2 (1–2) 0.450
b — — —
Number of medication
times/day 4 (3–5) 4 (3–6) 0.984
b — — —
Motor fluctuations, n (%) 30 (51) 33 (69) 0.061c — — —
Dyskinesias, n (%) 17 (29) 21 (45) 0.091c — — —
PD medications, n (%)
Levodopa 54 (95) 45 (94) 1.000c — — —
Dopamine agonists 31 (54) 34 (71) 0.084c — — —
COMT inhibitors 11 (19) 8 (17) 0.727c — — —
MAO-B inhibitors 23 (39) 22 (46) 0.572c — — —
Otheri 2 (4) 2 (4) 1.000c — — —
Advanced treatment, n (%)
Deep brain stimulation 1 (2) 2 (4) 0.586c — — —
S.c. apomorphine infusion 1 (2) 1 (2) 1.000c — — —
Levodopa/carbidopa
intestinal gel 4 (7) 1 (2) 0.372
c — — —
aData are median (q1-q3) unless otherwise noted. bMann–Whitney U test. cChi-Square test or Fisher’s exact test, as appropriate. dPossible scores, 0–4
(0� Poor, 4� Excellent). ePossible scores, 1–5 (1�No difficulties, 5�Extreme difficulties). fPossible stages, I–V (I�Mild unilateral disease, V�Confined to
bed or wheelchair unless aided). gPossible scores, 0–4 (0�None at all, 4�Extreme). hPossible scores, 0–4 (0�Never, 4�Always). iOther medications
included amantadine (n� 2), anticholinergics (n� 1), clozapine (n� 1). PADLS: Parkinson’s disease Activities of Daily Living Scale; PD: Parkinson’s disease;
COMT: Cathechol-O-Methyl Transferase; MAO-B: Mono Amine Oxidase type B; s.c.: subcutaneous.
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Table 2: Differences between and in persons with Parkinson’s disease before and after seven weeks of participation in the National
Parkinson School (intervention group) and after seven weeks of ordinal care (control group)a.
Intervention group (n� 48) Control group (n� 44) P-valueb
Health status (PDQ-8)d Baseline 28.1 (17.2–39.1) 25 (12.5–37.5) 0.301
Follow-up 23.4 (14.8–37.5) 23.4 (13.3–37.5) 0.713
P-valuec 0.028 0.644
Health valuation (EQ5D)e Baseline 0.87 (0.71–0.93) 0.86 (0.79–0.93) 0.473
Follow-up 0.88 (0.78–0.93) 0.86 (0.79–0.91) 0.279
P-valuec 0.023 0.866
Health education impact (heiQ)f
Health-directed activities Baseline 3.25 (2.75–3.75) 3.25 (2.75–3.75) 0.865
Follow-up 3.25 (2.75–3.75 3 (2.75–3.50) 0.344
P-valuec 0.323 0.437
Positive and active engagement in life Baseline 2.8 (2.6–3.2) 3 (2.6–3.4) 0.088
Follow-up 3 (2.8–3.2) 3 (2.6–3.4) 0.945
P-valuec 0.058 0.150
Emotional distress Baseline 2 (1.5–2.67) 2.17 (1.83–2.67) 0.529
Follow-up 2 (1.5–2.46) 1.83 (1.33–2.5) 0.536
P-valuec 0.436 0.020
Self-monitoring and insight Baseline 2.83 (2.58–3.17) 3 (2.5–3.17) 0.445
Follow-up 3 (2.71–3.17) 3 (2.67–3.17) 0.652
P-valuec 0.572 0.285
Constructive attitudes and approaches Baseline 3 (2.6–3.2) 3 (2.8–3.6) 0.075
Follow-up 3 (2.8–3.4) 3.2 (2.8–3.6) 0.971
P-valuec 0.003 0.845
Skills and techniques acquisition Baseline 2.5 (2–2.75) 2.88 (2.5–3.19) 0.002
Follow-up 3 (2.5–3) 2.75 (2.44–3) 0.463
P-valuec <0.001 0.464
Social integration and support Baseline 3 (2.4–3.6) 3 (2.8–3.4) 0.561
Follow-up 3 (2.8–3.6) 3 (2.6–3.4) 0.389
P-valuec 0.110 0.324
Health service navigation Baseline 2.9 (2.4–3.2) 3 (2.8–3.2) 0.112
Follow-up 3 (2.6–3.6) 3 (2.8–3.4) 0.903
P-valuec 0.286 0.368
Life satisfaction (LiSat-11)g
Life as a whole Baseline 4 (4–5) 5 (4–5) 0.031
Follow-up 4.5 (4–5) 4.5 (4–5) 0.868
P-valuec 0.117 0.011
Vocation Baseline 4 (3–5) 4 (4–5) 0.078
Follow-up 4 (4–5) 4.5 (4–5) 0.170
P-valuec 0.159 0.157
Economy Baseline 5 (4–5) 5 (5–5) 0.077
Follow-up 4 (4–5) 5 (4–5) 0.042
P-valuec 0.221 0.489
Leisure Baseline 4 (4–5) 5 (4–5) 0.105
Follow-up 4 (4–5) 5 (4–5) 0.889
P-valuec 1.000 0.028
Contacts Baseline 5 (4–5) 5 (4–5) 0.472
Follow-up 5 (4–5) 4 (4–5) 0.481
P-valuec 0.815 0.013
Sexual life Baseline 3 (2–4) 3 (2–4) 0.314
Follow-up 3 (2–4) 3 (2–5) 0.364
P-valuec 1.000 0.414
ADL Baseline 5 (4–5) 5 (4–6) 0.289
Follow-up 5 (4–5) 5 (4–6) 0.401
P-valuec 0.168 0.186
Family life Baseline 5 (4–6) 5 (4–6) 0.203
Follow-up 5 (4–6) 5 (5–6) 0.385
P-valuec 0.729 0.712
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understanding of PD had improved. (ere was a nonsig-
nificant trend (P � 0.073) for care partners to find the NPS
more helpful than PwPD in terms of goal setting.
3.6. Self-Reported Confounding Factors. PwPD and care
partners reported some factors that occurred between
baseline and follow-up that might have had an impact on
their mood and health. (ese included health problems or
deaths in the family (n� 3), own health issues (n� 3), im-
proved health (n� 3), birth of grandchildren (n� 4), and
changes in medication (n� 10). (ese factors were reported
and distributed in both the intervention and control groups.
Individual comparison of the assessments of persons
reporting possible confounders did not imply that their
answers had been influenced and were not extreme in any
way.
4. Discussion
(is study aimed to evaluate the effects of the self-man-
agement programme NPS for PwPD and their care partners
from the perspective of the participants. (e results suggest
that participation in the programme is associated with
improvements in self-assessed health status and in self-
management abilities among PwPD. Although most out-
comes did not reach statistical significance, the general
pattern reflected improvements in the intervention group,
whereas the control group tended to worsen or remain
stable. A similar but less obvious pattern was found for care
partners.
Our findings revealed improved perceived PD related as
well as general health status among PwPD following NPS
participation. (is is in line with previous results reported
for the PEPP [34, 35], suggesting that benefits associated
with the PEPP were retained despite the contextual adap-
tations that were made when developing the NPS. In parallel
with unaltered health status in the control group of PwPD
there was a deterioration in life satisfaction, which in turn
tended to improve in the intervention group. While the
reasons for this remain hypothetical, one possibility is that
the lack of health benefits and unaltered outlook and coping
skills may have played a role in decreasing satisfaction with
life. However, this cannot be determined based on the data
from the present study.
We found improvements in two domains of the heiQ:
constructive attitudes and approaches and skill and tech-
nique acquisition. Improvements in the former domain
reflect a shift in how persons view the impact of disease in
their everyday lives and are connected to a mindset of not
allowing disease to control their lives. Improvements in skill
and technique acquisition reflect better knowledge of skills
and techniques to manage and cope with the impact of PD,
including symptoms and problems in everyday life [48].(is
is in line with the intentions of the NPS. Previous studies
have found that PwPD and care partners wish to acquire the
knowledge and skills needed to improve their self-care
abilities and their interaction with health care services
through shared decision-making [65, 66]. (e improve-
ments according to the heiQ found here are therefore en-
couraging and suggest that the NPS can help PwPD acquire
the necessary knowledge and skills to facilitate active self-
care behaviours and participation in decisions regarding
their care.
(is study did not find any significant changes associated
with participation in the NPS among care partners. (is
might be due to the selection of instruments. For example,
we used the generic ZBI to assess burden, which may have
been too nonspecific to capture changes among care partners
of PwPD. In contrast to our findings, previous evaluations of
the PEPP reported improvements in care partners’ psy-
chosocial strain and need for help, as assessed using the
BELA-A-k questionnaire [33, 34]. Since the BELA-A-k was
developed specifically for care partners of care partners [67],
it might bemore suitable for capturing changes related to PD
related strain. However, the BELA-A-k is not available for
Table 2: Continued.
Intervention group (n� 48) Control group (n� 44) P-valueb
Partner relationship Baseline 5 (4–6) 6 (4.5–6) 0.266
Follow-up 5 (4.5–6) 5 (5–6) 0.841
P-valuec 0.696 0.244
Somatic health Baseline 4 (3–4) 4 (4–5) 0.068
Follow-up 4 (3–4) 4 (3–5) 0.930
P-valuec 0.263 0.054
Psychological health Baseline 4 (4–5) 5 (4–5) 0.367
Follow-up 4 (4–5) 5 (4–5) 0.088
P-valuec 0.442 0.536
Fatigue (PFS-16)h Baseline 28 (19–38.8) 32 (22–38) 0.814
Follow-up 32 (20–38) 27 (16–40) 0.946
P-valuec 0.164 0.832
aData are median (q1-q3). bMann–Whitney U test for comparisons between intervention and control groups. cWilcoxon’s signed rank test for comparisons
between baseline and follow-up within intervention and control groups. dPossible scores, 0–100 (100�worse health status). ePossible scores, 0–1 (1� better
valued health state). fPossible stages, 1–4 (4� better; except for emotional well-being, where 1� better). gPossible scores, 1–6 (6� higher life satisfaction).
hPossible scores, 0–64 (64�more fatigue). PDQ-8: the eight-item Parkinson’s Disease Questionnaire; EQ5D: the five-dimensional EuroQol Questionnaire;
heiQ: Health Education Impact Questionnaire; LiSat-11: the 11-item Life Satisfaction Checklist; PFS-16: the 16-item Parkinson Fatigue Scale.
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use in Sweden. Nevertheless, similar to the results from the
PEPP [33], care partners in this study expressed positive
experiences from the NPS, as indicated by generally high
scores on the heiQ-Programme evaluation questionnaire.
(is supports the value of the intervention, although the
outcome assessment tools were unable to reflect any im-
provements. It should also be noted that previous studies
have highlighted the importance of care partners being
involved and having knowledge of PD to be able to plan for
the future, maintain mutuality in relationships, and have a
good quality of life [68]. (e support of a care partner is
connected to higher levels of self-efficacy to engage in self-
care activities and a stronger sense of coherence among
PwPD [22, 69].
(e selection of outcome measures in this study was
partly influenced by previous studies of the PEPP
Table 3: Differences between care partners and persons with Parkinson’s disease before and after seven weeks of participation in the
National Parkinson School (intervention group) and after seven weeks of ordinal care (control group)a.
Intervention group (n� 30) Control group (n� 25) P-valueb
Health valuation (EQ5D)d Baseline 0.93 (0.88–0.97) 0.93 (0.88–0.97) 0.508
Follow-up 0.97 (0.88–0.97) 0.93 (0.88–0.97) 0.251
P-valuec 0.837 0.944
Life satisfaction (LiSat-11)e
Life as a whole Baseline 5 (4–5) 5 (4–6) 0.302
Follow-up 5 (4–5) 5 (4–6) 0.802
P-valuec 0.414 0.035
Vocation Baseline 5 (4–5) 5 (4–5.75) 0.388
Follow-up 5 (4.25–5) 5 (4–5) 0.261
P-valuec 0.655 0.109
Economy Baseline 5 (5–5) 5 (5–5.25) 0.515
Follow-up 5 (4–5.25) 5 (4–5) 0.945
P-valuec 0.317 0.132
Leisure Baseline 5 (4–5) 5 (4.75–5) 0.072
Follow-up 5 (4–5) 5 (4–5) 0.964
P-valuec 0.248 0.206
Contacts Baseline 5 (5–5) 5 (4–5.25) 0.666
Follow-up 5 (4–5) 5 (4–6) 0.671
P-valuec 0.366 0.564
Sexual life Baseline 4 (2–5) 4 (3.5–5) 0.509
Follow-up 4 (3–5) 4 (2.25–5) 0.776
P-valuec 0.491 0.417
ADL Baseline 6 (5–6) 6 (5–6) 0.586
Follow-up 6 (5–6) 6 (5.25–6) 0.486
P-valuec 0.891 0.317
Family life Baseline 5 (4–6) 5.5 (5–6) 0.227
Follow-up 6 (5–6) 6 (5–6) 0.801
P-valuec 0.290 0.655
Partner relationship Baseline 6 (5–6) 6 (5–6) 0.773
Follow-up 6 (5–6) 6 (5–6) 0.792
P-valuec 0.763 0.705
Somatic health Baseline 5 (4–5) 5 (4–5) 0.805
Follow-up 5 (5–5) 5 (4–5) 0.659
P-valuec 0.739 0.655
Psychological health Baseline 5 (5–6) 5 (4.75–6) 0.371
Follow-up 5 (5–6) 5 (4.5–6) 0.851
P-valuec 0.279 0.180
Fatigue (PFS-16)f Baseline 9 (0–17.75) 5 (1–19) 0.661
Follow-up 6 (0–20) 11.5 (1.25–25) 0.296
P-valuec 0.678 0.138
Caregiver burden (ZBI-22)g Baseline 7 (3–13) 6 (0.75–12.5) 0.495
Follow-up 8 (3.25–12.75) 5 (2–13.25) 0.659
P-valuec 0.090 0.548
aData are median (q1-q3). bMann–Whitney U test for comparisons between intervention and control groups. cWilcoxon’s signed rank test for comparisons
between baseline and follow-up within intervention and control groups. dPossible scores, 0-1 (1� better valued health state). ePossible scores, 1–6 (6� higher
life satisfaction). fPossible scores, 0–64 (64�more fatigue). gPossible scores, 0–48 (48�more burden). EQ5D: the 5-dimensional EuroQol questionnaire;
LiSat-11: the 11-item Life Satisfaction Checklist; PFS-16: the 16-item Parkinson Fatigue Scale; zbi-22: the 22-item Zarit Burden Interview.
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[31, 33–35]. (e reason for doing so was to investigate if the
NPS, which is influenced by the PEPP, showed similar re-
sults to those described by A’Campo and colleagues.
However, it may be questioned whether these outcomes are
the most appropriate ones for evaluating the effects of this
type of intervention. (erefore, we also added the heiQ,
which targets specific outcomes of self-management inter-
ventions rather than aspects that might also be influenced by
other circumstances in life [48]. In this perspective, our
observations suggest that the heiQ is suitable and sensitive
enough to detect effects of self-management interventions
among PwPD and should also be considered in future
studies. However, there may also be other outcomes that
should be considered. For example, studies investigating
outcomes of self-management interventions among persons
with other long-term conditions have assessed aspects such
as self-efficacy, coping, sense of coherence, and self-man-
agement of daily activities [70], that may be appropriate to
include in future studies of the NPS to further improve
understanding of programme effects. Indeed, one study of
the PEPP included several such outcomes and found ben-
eficial effects regarding coping [36]. Furthermore, depressive
symptoms are common in PD and can affect function and
thereby the effect of self-management interventions as well
as influencing responses to questionnaires, adding a tool to
assess depression should be considered [71, 72]. Finally, the
NPS is designed as a dyadic intervention intended to pro-
mote self-management and coping in the context of shared
everyday life. (erefore, assessing possible effects on mu-
tuality could also be of interest to understand the impact of
the programme [68].
(e current study design prevents any conclusions re-
garding the long-term effects of the NPS. However, previous
studies have shown that effects of this type of intervention can
last up to three months among PwPD [35, 36]. Assessment of
long-term effects that can be influenced by other factors than
educational interventions is difficult and the risk of drawing
false conclusions in either direction is apparent [48]. In ad-
dition, with a progressive disease such as PD it is known that
as symptom burden increases, satisfaction with life will de-
cline for both persons affected and their care partners
[52, 73, 74].(is impact due to progression of the disease itself
should be considered when evaluating long-term outcomes. If
the long-term effects of self-management interventions for
PwPD are investigated, a reasonable timeframe and alter-
native outcome assessment tools will be needed.
As this study was designed to reflect the outcomes of the
NPS in clinical care, the selection of participants was not
restricted by narrow selection criteria. Instead, health care
professionals invited persons to the programme based upon
their clinical judgement, for example, persons in a certain
stage of disease or with an expressed interest in these types of
interventions. Accordingly, participants showed a relatively
large degree of heterogeneity in background characteristics.
While this may have introduced a selection bias and limited
the possibilities to detect changes in outcomes, it may also
better reflect clinical reality.
Finally, it may be argued that the sample size was in-
sufficient to allow fair detection of programme effects,
particularly among care partners. While a more even dis-
tribution of PwPD and care partners would have been de-
sirable, the current ratio appears reflective of clinical reality.
Furthermore, our sample size estimation was based on an
outcome measure previously used as a primary end-point
among PwPD [34], not care partners, since the primary care
partner outcome measure in previous studies was not
available for use in this study. (e results of this study for
care partners should therefore be interpreted with some
caution. A larger sample of PwPD in the intervention group
would also have allowed for subgroup analyses, for example,
regarding disease severity. (is could have added valuable
information regarding when the NPS is most useful to
participants and may therefore be of value to consider in
future research. For example, a previous qualitative study on
the NPS indicated that PwPD value different programme
components differently depending onstage and duration of
disease [39]. In addition, future studies should also consider
health economic aspects to better understand the full value
and implications of the NPS.
5. Conclusions
(e NPS is the first structured attempt in the Swedish
healthcare to provide a uniform patient education and self-
Table 4: Results of the heiQ-Program evaluation among persons with Parkinson’s disease and care partners after participation in the
National Parkinson Schoola,b.
Items (abridged) Persons with Parkinson’s disease (n� 48) Care partners (n� 26) P-valuee
I will tell people that the NPS is very worthwhileb 5 (4–5) 5 (4.75–5) 0.349
(e NPS has helped me set reasonable and achievable goalsb 4 (4–5) 5 (4–5) 0.073
I trust the information and advice given in the NPSb 5 (4–6) 5 (5–5) 0.649
NPS leaders were very well-organizedb 5 (4–5) 5 (4–6) 0.091
It was worth my time and effort to take part in the NPSb 5 (4–6) 5 (5–6) 0.405
Difficult topics and discussions were handled wellb 5 (4–5) 5 (5–6) 0.136
NPS content was very relevant to my situationb 5 (4–5) 5 (4–5) 0.309
Everyone had the chance to speak if they wanted tob 5 (5–6) 5.5 (5–6) 0.425
(e group worked very well togetherb 5 (4–5) 5 (4.5–5.5) 0.158
My understanding of PD has improvedc,d 3 (2–3) 3 (2–3) 0.283
My expectations of the NPS were metc,d 3 (2–3) 3 (2–3) 0.177
aData are median (q1-q3). bPossible scores, 1–6 (1�Totally disagree, 6�Totally agree). cStudy specific items not included in the original heiQ-Program
evaluation questionnaire. dPossible scores, 1–3 (1�Disagree, 3�Agree). eMann–Whitney U test.
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management model for PwPD and their care partners. (is
study shows that the programme can improve health and the
skills required to handle disease and manage symptoms in
everyday life and can strengthen the mindset of persons
affected by PD of being in charge and not allowing disease to
control life. Although we failed to detect any effects among
care partners, the NPS was considered at least as valuable by
care partners as by PwPD.(ese results are encouraging and
illustrate that the programme is beneficial and valuable for
participants. (e NPS should therefore be offered as an
integrated part of a holistic person-centred standard care,
and resources should be allocated for the provision of the
programme. Further studies are needed to better understand
the effects of the NPS on participants as well as the impact on
health care utilisation and organization.
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